Publications by authors named "J Luis Gorriz"
Importance: Chronic kidney disease (CKD) is a global health priority affecting almost 1 billion people. New therapeutic options and clinical trial innovations such as adaptive platform trials provide an opportunity to efficiently test combination therapies.
Objective: To describe the design and baseline results of the Global Kidney Patient Trials Network (GKPTN) and the design and structure of the global adaptive platform clinical trial Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE) to find new therapeutic options and treatments for people with kidney disease.
SGLT-2 inhibitors (SGLT-2is) are considered to be a first-line treatment for common conditions like type 2 diabetes, chronic kidney disease, and heart failure due to their proven ability to reduce cardiovascular and renal morbidity and mortality. Despite these benefits, SGLT-2is are associated with certain adverse effects (AEs), particularly genitourinary (GU) events, which can lead to treatment discontinuation in some patients. Preventing these AEs is essential for maintaining the cardiorenal benefits of SGLT-2is.
View Article and Find Full Text PDFArticle Synopsis
- Chronic kidney disease (CKD) poses significant challenges for healthcare systems due to its high morbidity and resource demands, prompting a need for an optimal care model through a multidisciplinary approach.
- A panel of 59 CKD experts identified 38 key factors for improving patient care, focusing on enhancing CKD visibility, prevention, early diagnosis, coordinated monitoring, and training for both healthcare providers and patients.
- The study emphasizes a collective agreement on prioritizing CKD care by fostering prevention, early detection, and comprehensive monitoring to improve outcomes at institutional and societal levels.
Article Synopsis
- Semaglutide, a drug for type 2 diabetes, shows promise in reducing albuminuria and slowing kidney disease progression in patients with chronic kidney disease (CKD) in a double-blind clinical trial.
- The study involved 101 participants, comparing those receiving 2.4 mg of semaglutide weekly to a placebo, with a focus on changes in urine albumin-to-creatinine ratio after 24 weeks.
- Results indicated a significant 52.1% reduction in albuminuria for the semaglutide group, although gastrointestinal side effects were more common compared to the placebo group.
Key Points: Increasing doses of the endothelin receptor antagonist zibotentan and lower eGFR were associated with a higher risk of fluid retention. The higher risk of fluid retention could be attenuated by the combination of zibotentan with the sodium-glucose cotransporter 2 inhibitor dapagliflozin.
Background: Endothelin receptor antagonists (ERAs) reduce albuminuria but are limited by fluid retention risk, particularly in patients with CKD.